Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials

Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study

(2016) K. Suzuki et al.   ANNALS OF ONCOLOGY

Antiemetics: American Society of Clinical Oncology Focused Guideline Update

(2016) Paul J. Hesketh et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

(2014) P. J. Hesketh et al.   ANNALS OF ONCOLOGY

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

(2012) M. Aapro et al.   ANNALS OF ONCOLOGY

Rikkunshito Improves the Symptoms in Patients with Functional Dyspepsia, Accompanied by an Increase in the Level of Plasma Ghrelin

(2011) Makoto Arai et al.   HEPATO-GASTROENTEROLOGY

Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan

(2011) Kazunari Tominaga et al.   JOURNAL OF GASTROENTEROLOGY

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

(2010) M. Aapro et al.   ANNALS OF ONCOLOGY

Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy

(2010) Flavia Longo et al.   SUPPORTIVE CARE IN CANCER

Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009

(2010) Karin Jordan et al.   SUPPORTIVE CARE IN CANCER

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

(2010) Tobias Engel Ayer Botrel et al.   SUPPORTIVE CARE IN CANCER

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

(2009) Jørn Herrstedt et al.   JOURNAL OF CLINICAL ONCOLOGY

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER

Selective Serotonin Reuptake Inhibitors Modify Physiological Gastrointestinal Motor Activities via 5-HT2c Receptor and Acyl Ghrelin

(2008) Naoki Fujitsuka et al.   BIOLOGICAL PSYCHIATRY

Rikkunshito, an Herbal Medicine, Suppresses Cisplatin-Induced Anorexia in Rats Via 5-HT2 Receptor Antagonism

(2008) Hiroshi Takeda et al.   GASTROENTEROLOGY

A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia

(2008) Katsuyoshi Mizukami et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Chemotherapy-Induced Nausea and Vomiting

(2008) Paul J. Hesketh   NEW ENGLAND JOURNAL OF MEDICINE